X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (10) 10
index medicus (10) 10
female (9) 9
aged (8) 8
middle aged (8) 8
adult (7) 7
male (7) 7
oncology (6) 6
abridged index medicus (4) 4
chemotherapy (4) 4
hematology (4) 4
aged, 80 and over (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
bortezomib (3) 3
cancer (3) 3
care and treatment (3) 3
dexamethasone (3) 3
dexamethasone - administration & dosage (3) 3
disease-free survival (3) 3
lenalidomide (3) 3
prognosis (3) 3
rituximab (3) 3
survival (3) 3
transplantation (3) 3
bortezomib - administration & dosage (2) 2
cyclophosphamide (2) 2
cyclophosphamide - administration & dosage (2) 2
diagnosis (2) 2
follow-up (2) 2
follow-up studies (2) 2
france (2) 2
hematology, oncology and palliative medicine (2) 2
hematopoietic stem cell transplantation (2) 2
intention to treat analysis (2) 2
lymphoma (2) 2
lymphomas (2) 2
methotrexate (2) 2
multiple myeloma - drug therapy (2) 2
patients (2) 2
prospective studies (2) 2
stem cell transplantation (2) 2
stem cells (2) 2
survival analysis (2) 2
thalidomide - administration & dosage (2) 2
thalidomide - adverse effects (2) 2
therapy (2) 2
time factors (2) 2
treatment outcome (2) 2
young adult (2) 2
[sdv.can]life sciences [q-bio]/cancer (1) 1
activation (1) 1
acute kidney injury (1) 1
acute kidney injury - etiology (1) 1
acute kidney injury - mortality (1) 1
acute kidney injury - therapy (1) 1
acute lymphoblastic-leukemia (1) 1
acute-renal-failure (1) 1
administration, oral (1) 1
adolescent (1) 1
age factors (1) 1
allogenic transplantation (1) 1
allografts (1) 1
amino acids (1) 1
analysis (1) 1
anemia - chemically induced (1) 1
angiogenesis inhibitors - administration & dosage (1) 1
angiogenesis inhibitors - adverse effects (1) 1
angiogenesis inhibitors - therapeutic use (1) 1
anti-inflammatory agents - therapeutic use (1) 1
antibodies, monoclonal, murine-derived - administration & dosage (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
apoptosis - physiology (1) 1
apoptosis - radiation effects (1) 1
asparaginase (1) 1
bcl-2 (1) 1
bcr-abl (1) 1
belgium (1) 1
biomarker (1) 1
biomarkers, tumor - cerebrospinal fluid (1) 1
biopsy (1) 1
blood transplantation (1) 1
bone-marrow transplantation (1) 1
bortezomib - adverse effects (1) 1
bortezomib-based regimens (1) 1
brain radiotherapy (1) 1
breast neoplasms - therapy (1) 1
busulfan - administration & dosage (1) 1
carfilzomib (1) 1
case-control studies (1) 1
cell biology (1) 1
cells, cultured (1) 1
central nervous system (1) 1
central nervous system neoplasms - cerebrospinal fluid (1) 1
central nervous system neoplasms - diagnosis (1) 1
central nervous system neoplasms - drug therapy (1) 1
central nervous system neoplasms - mortality (1) 1
central nervous system neoplasms - pathology (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA, ISSN 0098-7484, 12/2017, Volume 318, Issue 21, pp. 2099 - 2110
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5233 - 5233
Abstract Background: Acute Myeloid Leukemia (AML) is a heterogeneous disease carrying a dismal prognosis. This outcome is the consequence of patient factors... 
Journal Article
Blood, ISSN 0006-4971, 05/2016, Volume 127, Issue 21, pp. 2569 - 2574
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2013, Volume 49, Issue 13, pp. 2869 - 2876
Journal Article
Blood, ISSN 0006-4971, 08/2016, Volume 128, Issue 6, pp. 774 - 782
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 4597 - 4597
Abstract Introduction ASCT is a cornerstone in lymphoma therapeutics, especially in the relapse setting. BEAM (carmustine, etoposide, cytarabine, and... 
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 4884 - 4884
Abstract Background: Cancer-related anemia is a very frequent condition of complex physiopathology which impacts heavily on quality of life, morbidity and... 
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 61, pp. 69 - 76
Journal Article
Journal of Neuro-Oncology, ISSN 0167-594X, 11/2011, Volume 105, Issue 2, pp. 409 - 414
The aim of this study was to evaluate the efficacy and toxicity of two chemotherapy regimens based on platinum and cytarabine in association with etoposide and... 
Neurology | Medicine & Public Health | Stem cell transplantation | Oncology | Salvage treatment | Non Hodgkin lymphoma | Primary CNS lymphoma Chemotherapy | STEM-CELL RESCUE | INTENSIVE CHEMOTHERAPY | DEXAMETHASONE | INTRAOCULAR LYMPHOMA | HIGH-DOSE CYTARABINE | CLINICAL NEUROLOGY | CISPLATIN | ONCOLOGY | RECURRENT PRIMARY CNS | RITUXIMAB | NON-HODGKINS-LYMPHOMA | ESHAP | Prognosis | Follow-Up Studies | Methylprednisolone - therapeutic use | Thiotepa - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Male | Neoplasm Recurrence, Local - mortality | Busulfan - administration & dosage | Lymphoma - mortality | Cisplatin - administration & dosage | Neoplasm Recurrence, Local - pathology | Young Adult | Lymphoma - drug therapy | Anti-Inflammatory Agents - therapeutic use | Adult | Female | Lymphoma - pathology | Retrospective Studies | Dexamethasone - administration & dosage | Rituximab | Etoposide - administration & dosage | Cytarabine - administration & dosage | Central Nervous System Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Central Nervous System Neoplasms - drug therapy | Central Nervous System Neoplasms - mortality | Care and treatment | Dexamethasone | Clouds | Central nervous system | Etoposide | Transplantation | Non-Hodgkin's lymphomas | Methylprednisolone | Hematopoietic stem cells | Chemotherapy | Cyclophosphamide | Analysis | Stem cells | Cancer | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2019, Volume 37, Issue 31, pp. 2815 - 2824
PURPOSE The PRIMA study (ClinicalTrials.gov identifier: NCT00140582 ) established that 2 years of rituximab maintenance after first-line immunochemotherapy... 
Journal Article
Hematologie, ISSN 1264-7527, 2014, Volume 20, Issue 2, pp. 111 - 115
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 1619 - 1619
Abstract Reliable biomarkers of primary central nervous system lymphoma (PCNSL) are needed to support the magnetic resonance imaging (MRI) findings especially... 
Journal Article
Bone Marrow Transplantation, ISSN 0268-3369, 03/2017, Volume 52, Issue 3, pp. 372 - 380
Journal Article
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 07/2019, p. JCO1901073
The PRIMA study (ClinicalTrials.gov identifier: NCT00140582) established that 2 years of rituximab maintenance after first-line immunochemotherapy... 
Journal Article
Journal Article
Clinical Nuclear Medicine, ISSN 0363-9762, 02/2008, Volume 33, Issue 2, pp. 111 - 112
Journal Article